ICMR - NICED


ICMR-National Institute of Cholera and Enteric Diseases

आई सी एम आर - राष्ट्रीय कॉलरा और आंत्र रोग संस्थान

Department of Health Research, Ministry of Health and Family Welfare, Government of India
स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य और परिवार कल्याण मंत्रालय, भारत सरकार
WHO Collaborating Centre For Research and Training On Diarrhoeal Diseases

NICED : Scientists

Dr. Hemanta Koley

Dr. Hemanta Koley

Field of Research:

  1. Signal transduction pathways of immune and inflammatory cells during diarrhoea.
  2. Study the nature of protection against diarrheal pathogens in different animal models.
  3. Development of Ideal Oral Rehydration Solution to use in secretary diarrhoea.
  4. Study of drug development again multidrug resistant enteric organisms.
  5. Eradication of multidrug resistant enteric organisms through OMVs livestock autovaccination.
  6. Combination vaccine development against diarrheal diseases.
     

Educational Background:

After completion of his master degree in Physiology from University College of Science & Technology, Calcutta University, he joined in National institute of Cholera and Enteric Diseases, Beliaghata, Calcutta for his Ph. D. degree under super guidance of Dr. G.Balakrish Nair, PhD, FNA, FNASc, FTWAS, FAAM. In 1996, he joined as Associate Professor in Dept. Physiology, College of Medical Sciences-Nepal, where he devoted entire heartily in teaching medical students till 2000.

In the meantime Dr. Koley got opportunity for Post-Doctoral research under Dr Dipak Sarkar, at Dept of Physiology, Rutgers -The State University of New Jersey, New Brunswick, USA.

After completion of one year in Rutgers University, Dr. Koley moved to Boston, joined in VA Health Care , Harvard Medical School as Research Associate and worked there on “Molecular mechanism of Barrett’s esophagus and to work on Adenocarcinoma” under leadership of Prof. R K Goyal, Mallinckrodt Professor of Medicine, renowned gastroenterologist.
.

Research Achievement:

  1. Secured patent for a process for the preparation of Cholera Vaccine-VA1.3 (European Patent Office; Patent No.- 97309957.5-2105 on 19/05/98) (https://vaccine.icmr.org.in/images/pdf/Cholera_P2.pdf)
  2. Patent for a process for the isolation of a non-toxigenic Vibrio Cholerae strain. (European Patent Office; Patent No. - 97309957.5-2105 on 19/05/98 ( https://vaccine.icmr.org.in/images/pdf/Cholera_P2.pdf)
  3. Patent application titled ‘A Multi-Serotype Outer Membrane Vesicles (MOMV) of shigellae as a novel candidate vaccine’ (PCT/IN2014/000369) https://vaccine.icmr.org.in/images/pdf/Shigella_P_1.pdf
  4. Patent application for: “Alginate chitosan Nano formulation of Omp-A, a Shigella protein subunit vaccine International application # PCT/IN20 17/000094
    https://vaccine.icmr.org.in/images/pdf/Shigella_P_2.pdf
  5. Novel Shigella Vaccine Formulation and Process to Prepare Thereof , Application number, filing date and Number 19831538.4 / 02.07.2019 / WO2019IN50492 ( https://vaccine.icmr.org.in/images/pdf/Novel_Shigella_Vaccine.pdf )
  6. Patent application for: “'A Bivalent outer membrane vesicles (BOMVs) based vaccine against typhoidal salmonellae', patent application no. 201711011707” ICMR New Delhi. (PCT/IN2018/050158) PCT/IN2018/050158.( https://vaccine.icmr.org.in/images/pdf/typhoid_P_1.pdf  )
  7. Patent application for: “Fortified Soy-Yogurt Composition for Anti-Hypercholestrolemic Effect” the said patent application has been filed on May 20, 2019, with application number PCT/IN2020/050441
  8. Development and evaluation of a bivalent invasive non-typhoidal Salmonella outer membrane vesicles (BINTSOMVs) based vaccine against non-typhoidal Salmonella mediated gastroenteritis. 23rd June, 2020, Applied to ICMR for Patent File.
  9. "Aqueous arabinose solution: novel product for cholera diarrhea management". a patent application has been filed on 14th Dec. 2020 and patent application no. 202011054354.

Shigella vaccine

Hilleman Laboratories and ICMR-NICED has tied up to commercialize Shigella vaccine. After signing of the MoU, necessary technology transfer was done to initiate the work. After developing and optimizing the process, MSD Welcome Trust Hilleman Laboratories will be manufacturing the product on a non-GMP (i.e. non-Good Manufacturing Practice) level. And thus NICED continues to work on Shigella Vaccine to make further in roads towards its unexplored areas. ICMR licensed the technology further scaling up and commercialisation to Hilleman Laboratories Pvt. Ltd., meeting at New Delhi on April 23, 2019 at the ICMR Headquarters. BCIL executed the License Agreement with NICED on behalf of ICMR and Hilleman Labs. Shigella vaccine candidate has been awarded a research grant by the European and Developing Countries Clinical Trials Partnership (EDCTP). MSD Welcome Trust Hilleman Laboratories will be manufacturing the low cost product, Phase I & II proof-of-concept will be in Africa in 2023.

 

General Information
Name Dr. Hemanta Koley
Designation Scientist E
Date of joining ICMR 1st October 2004
Date of joining present post 1st September 2016
Discipline Physiologist
Division Bacteriology
Specialization Bacteriologist
Email : hemantakoley@hotmail.com
Academic Qualification  
Graduation BSc in Physiology.
Post Graduation MSc in Physiology
Doctoral Physiology

Profile

Research Experience

Dr Hemanta Koley, after completion of his Masters and PhD in Physiology, he continued to excel being a post-doctoral fellow at The State University of New Jersey and Harvard Medical School, USA. He is attached with ICMR-National Institute of Cholera and Enteric diseases from 2004 as a scientist in the Division of Bacteriology. He dedicated more than seventeen years innovative efforts to come up with an array of effective vaccine candidates against the enteric pathogens like Vibrio cholerae, Shigella, Typhoidal and Non-typhoidal Salmonella. Being an accomplished physiologist, he established new animal models for therapeutic investigation. These approaches range from conventional to next generation vaccine candidates. He already has seven patents in his credit and has applied for another two. Dr. Koley is also a dedicated teacher and trainer of the students. Nine graduate students completed their PhD degree under his supervision and many more are in line. His distinguished research career is being enriched with pubmed index 85 publications in peer-reviewed journals. He was felicitated with several national and international honors. It is his extremely cooperative and congenial research attitude which kindles plethora of national and international collaborations specially Japan and USA. In recent times, he acts the most important bridge between ICMR and Industrial sector to mobilize the Shigella vaccine candidate for commercialization.
 

Research Interest

Laboratory has identified a number of potential vaccine candidates like outer membrane vesicles, Bacterial ghost antigen, Heat killed bacterial antigen, Formalin treated bacterial antigen, Live attenuated bacterial antigen, Nanoparticle formulation specially chitosan-alginate ompA nanoparticle, subunit vaccine

Research multiple projects are focus on the development of novel vaccine candidate for the livestock and human against enteric pathogens like Vibrio cholerae, Shigella, Typhoidal and Non-typhoidal Salmonella, Dirrhoeagenic Escherichia coli( DEC), Campylobacter, and Helicobacter pylori.

Special expertise on outer membrane vesicles based studies on various animal models, like Mouse, Rat, Hamster, Guinea pig, Rabbit, Chicken and Zebra fish.

Long path programme of the laboratory is to develop a single vaccine candidate against all enteric pathogens.
.

Memberships

National Membership:

  1. Life member of Physiological Society of India. (Membership # 239)
  2. Life member of Indian Science Congress Association. (Membership # L5792)
     

Awards

  1. Young Scientist Award in IUPS International Congress 2001, Christchurch, New Zealand, August 26-31, 2001
  2. Invited Lecture, UGC Sponsored National Seminar, Dept. of Physiology, Presidency College, Kolkata, 19th December, 2008.
  3. JICA – Fellowship: Worked with Dr. Shinji Yamasaki, Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1 Gakuen-cho, Nakaku, Sakai, Osaka Prefecture University, Osaka, Japan form 2007-09-19 to 2008-03-15
  4. Invited Oration Lecture: on “Dr. (Mrs.) Chitralekha Mukherjee Memorial Oration-2010” at St. John’s Medical College, Bangalore on 16th December 2010
  5. Invited lecture in National Seminar on “Biotechnology for People: Applications and Awareness” Prasannadeb Women’s College, Club road, Jalpaiguri-735101, December 4-5, 2012
  6. Invited lecture on University teacher training course conducted by Calcutta University 2014
  7. Invited special lecture at "Asian Society of Diarrhoeal Disease and Nutrition" conference (ASCODD) at Kochi between October 30 to November 1, 2017.
  8. Invited Lecture on “Shigella Vaccine” Occasion of MSD-Hilleman Laboratory Science day workshop on 2nd Nov 2017 at Imperial Hotel, New Delhi.

.

Collaborations:

National Level Collaboration:

  • Dr. Shantanu Tamuly
    Department of Veterinary Biochemistry, College of Veterinary Science, Assam Agricultural University, Khanapara, Guwahati-22. Assam
  • Dr. Devasish Chowdhury
    Physical Sciences Division
    Institute of Advanced Study in Science and Technology, Guwahati
  • Dr Dhirendra S. Katti
    Professor
    Department of Biological Sciences and Bioengineering
    Indian Institute of Technology - Kanpur
    Kanpur - 208016, UP
    INDIA
     

International Level Collaboration:

  • Dr Jiro Mitobe M.D.-Ph.D
    Department of Bacteriology I
    National Institute of Infectious Diseases
    1-23-1 Toyama Shinjuku Tokyo 162-8640
    Japan
  • Dr Jeffrey H. Withey, Ph.D.
    Associate Professor
    Department of Immunology and Microbiology
    Wayne State University School of Medicine
    Detroit, MI 48201
    USA
  • Dr. Deanna L. Gibson, Ph.D.
    Associate Professor, Biology
    University of British Columbia, Okanagan campus
    250-807-8790 / deanna.gibson@ubc.ca
    3187 University Way, Kelowna BC V1V 1V7
    Canada
     

Alumni Ph.D. Students

  • Dr Nivedita Roy.
    Present affiliation: Post-Doctoral fellow. Division of Molecular Medicine, Bose Institute, Kolkata, West Bengal, India.
  • Dr Soumik Barman.
    Past affiliation: Post-Doctoral fellow. Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
    Present affiliation: Post-Doctoral fellow. Department of Pediatrics, University of Washington School of Medicine, Seattle Children's Research Institute, Seattle, USA.
  • Dr Soma Mitra.
    Past affiliation: Post-Doctoral fellow. Department of Bacteriology, National Institute of Infectious Diseases (NIID), Japan.
    Present affiliation: ICMR Post-Doctoral fellow. Division of Bacteriology, ICMR-NICED.
  • Dr Dhrubajyoti Nag.
    Past affiliation: Post-Doctoral fellow. University of Kansas Medical Center. USA.
    Present affiliation: Post-Doctoral fellow. Wayne State University, USA.
  • Dr Ritam Sinha.
    Past affiliation: Research Associate, Department of Biological Sciences, IISER,India .
    Present affiliation: Post-Doctoral Research Associate, Department of Microbiology and Molecular Genetics, Michigan State University. USA.
  • Debanjana Bhattachariya,
    Present affiliation: Department of Life Science & Biotechnology, Jadavpur University, 188 Raja S.C. Mullick Road, Kolkata, 700032, India.
  • Dr Sounak Sarkar,
    Present affiliation: Molecular Biologist, West Bengal Health Service, Kolkata-700091
  • Dr Debaki Ranjan Howlader
    Present affiliation: Postdoctoral Researcher Pharmaceutical Chemistry
    The University of Kansas, 1450 Jayhawk Blvd, Lawrence, KS 66045, United States
     

Projects

Extramural Project

  1. Development of Nanoparticle or Microparticle Adjuvanted Subunit Oral Vaccine against Poultry Salmonellosis, DBT, New Delhi.
  2. Studies on immunogenicity and protective efficacy of multi-serotype OMVs of circulating Salmonella strains in chicken model, DST, Kolkata
  3. Development and evaluation of a heat killed multi-serotype oral Shigella vaccine- Japan Initiative for Global Research Network on Infectious Diseases (J-GRID), Ministry of Education, Culture, Sports, Science and Technology of Japan.
  4. Development of Shigella vaccine based on the virulence gene expression. Funded by Department of Bacteriology, National Institute of Infectious Diseases, Shinjuku, Tokyo 162-8640, Japan.
  5. Vaccination and protection studies for a targeted Nanoparticulate oral vaccine against shigellosis. DBT, New Delhi.
  6. Potential probiotic application of novel commensal E. coli with antagonistic activity against different enteric pathogen. Funded by Indian Council of Medical Research V. Ramalingaswami Bhawan, P.O. Box No. 4911
  7. Development of a combination next generation Outer Membrane Vesicles (OMVs) based immunogen to reduce multi drug resistant non-typhoidal Salmonella and Campylobacter mediated clinical health burden. Funded by Indian Council of Medical Research V. Ramalingaswami Bhawan, P.O. Box No. 4911 Ansari Nagar, New Delhi - 110029, India
     

Intramural Project

  1.  Studies on colonization ability of tcp-ve Vibrio cholerae strains in animal models. ICMR-
  2. Studies on a novel approach of using outer membrane vesicles (OMVs) of Shigella as a candidate vaccine in animal models.
  3. Evaluation of immunogenicity and protective efficacy of ∆tolA Shigella OMVs in animal model
  4. Formulation of a novel Outer Membrane Vesicle (OMVs) based immunogen from S. Typhi and Paratyphi A and the induction of adaptive immunity and protective efficacy in mice model.
  5. Comparative Immunogenicity and protective efficacy studies with OMVs, Heat killed, Ghost Cell Bivalent typhoidal Salmonella immunogen in mice model.
     

Laboratory Members

Pre-doctoral Fellows:

  1. Mr . Vivek Mandal Senior Research Fellow, CSIR
  2. Mr Pralay Halder Junior Research Fellow, ICMR
  3. Mr Soumalya Benerjee, Junior Research Fellow , UGC
  4. Mr Sanjib Das, Junior Research Fellow , UGC
     

Thesis Preparation:

  • Dr Soma Mitra,ICMR
  • Dr Samadrita Sengupta,ICMR
  • Dr Sanjucta Kar,ICMR

Thesis Submitted:

  • Ms. Priyadarshini Mukherjee, Senior Research Fellow, UGC

Post-Doctoral Research Associate

  • Dr. Soma Mitra, ICMR
  • Dr Samardrita Sengupta ICMR
  • Dr Sanjukta Kar, ICMR
     

Travel to foreign countries to attend conference/ meetings

  1. 54th US-Japan Joint Panel Conference on Cholera and Other Bacterial Enteric Infections. 10th-13th December, 2019 Osaka, Japan.
  2. US-Japan Cooperative Medical Sciences Program (USJCMSP) 21st International Conference on Emerging Infectious Diseases in the Pacific Rim, Hanoi Vietnam during Feb 26 to March 1, 2019.
  3. International Conference on Emerging Infectious Diseases in the Pacific Rim (EID)” and associated Workshop on Cholera and Other Bacterial Enteric Infections on Feb. 7-10, 2017 in Seoul, Korea
  4. Japan India Bilateral Meeting on the collaborative research projects” at the National Institute of Infectious Diseases (NIID), January 25th-26th, 2016 Tokyo, Japan
  5. Annual Asian-African Research Forum on Emerging and Re-emerging Infections to be held in Tokyo, Japan Okayama University Forum for Emerging Enteric Diseases in Okayama, Japan Joint Meeting and Conference of the US-Japan Panel on Cholera and Other Bacterial Enteric Infections 23-1-2013 26-1-2013 Okayama24-1-2013-27-1-2013, Japan
  6. Annual Asia-African Research Forum” organized by the Japan Initiative for Global Research Network on Infectious Diseases, January 11 and 12, 2012. Kobe, Japan
  7. US-Japan Panel on Cholera and Other Bacterial Enteric Infections at Kyoto, Japan during December 12-14, 2012 in Chiba, Japan
     

Publications

2021

  1. Maiti S, Howlader DR, Halder P, Bhaumik U, Dutta M, Dutta S, Koley H. Bivalent non-typhoidal Salmonella outer membrane vesicles immunized mice sera confer passive protection against gastroenteritis in a suckling mice model. Vaccine. 2021 Jan 8;39(2):380-393.
  2. Das S, Chourashi R, Mukherjee P, Kundu S, Koley H, Dutta M, Mukhopadhyay AK, Okamoto K, Chatterjee NS. Inhibition of growth and virulence of Vibrio cholera by carvacrol, an essential oil component of Origanum spp. J Appl Microbiol. 2021 Feb 5. doi: 10.1111/jam.15022. Epub ahead of print. PMID: 33544959.

2020

  1. Pant A, Bag S, Saha B, Verma J, Kumar P, Banerjee S, Kumar B, Kumar Y, Desigamani A, Maiti S, Maiti TK, Banerjee SK, Bhadra RK, Koley H, Dutta S, Nair GB, Ramamurthy T, Das B. Molecular insights into the genome dynamics and interactions between core and acquired genomes of <i>Vibrio cholerae</i>. Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23762-23773. doi: 10.1073/pnas.2006283117. Epub 2020 Sep 1. PMID: 32873641; PMCID: PMC7519391.
  2. Golder T, Mukhopadhyay AK, Koley H, Nandy RK. Nonmetabolizable Arabinose Inhibits Vibrio cholerae Growth in M9 Medium with Gluconate as the Sole Carbon Source. Jpn J Infect Dis. 2020 Sep 24;73(5):343-348. doi: 10.7883/yoken.JJID.2019.304. Epub 2020 Apr 30. PMID: 32350213..
  3. Bhattacharya D, Sinha R, Mukherjee P, Howlader DR, Nag D, Sarkar S, Koley H, Withey JH, Gachhui R. Anti-virulence activity of polyphenolic fraction isolated from Kombucha against Vibrio cholerae. Microb Pathog. 2020 Mar;140:103927. doi: 10.1016/j.micpath.2019.103927. Epub 2019 Dec 14. PMID: 31846743..

2019

  1. Mukherjee P, Mondal V, Bhaumik U, Sinha R, Sarkar S, Mitra S, Howlader DR, Maiti S, Mukhopadhyay AK, Dutta S, Koley H. Studies on formulation of a combination heat killed immunogen from diarrheagenic Escherichia coli and Vibrio cholerae in RITARD model. Microbes Infect. 2019 Oct - Nov;21(8-9):368-376  Pubmed
  2. Ghosh P, Sinha R, Samanta P, Saha DR, Koley H, Dutta S, Okamoto K, Ghosh A,Ramamurthy T, Mukhopadhyay AK. Haitian Variant Vibrio cholerae O1 StrainsManifest Higher Virulence in Animal Models. Front Microbiol. 2019 Feb 5;10:111  Pubmed
  3. Dey TK, Koley H, Ghosh M, Dey S, Dhar P. Effects of nano-sizing on lipidbioaccessibility and ex vivo bioavailability from EPA-DHA rich oil in waternanoemulsion. Food Chem. 2019 Mar 1;275:135-142.   Pubmed
  4. Withey JH, Nag D, Plecha SC, Sinha R, Koley H. Erratum for Withey et al.,"Conjugated Linoleic Acid Reduces Cholera Toxin Production In Vitro and In Vivoby Inhibiting Vibrio choleraeToxT Activity". Antimicrob Agents Chemother. 2019Jan 29;63(2). pii: e02493-18 Pubmed
  5. Bag PK, Roy N, Acharyya S, Saha DR, Koley H, Sarkar P, Bhowmik P. In vivofluid accumulation-inhibitory, anticolonization and anti-inflammatory and invitro biofilm-inhibitory activities of methyl gallate isolated from Terminaliachebula against fluoroquinolones resistant Vibrio cholerae. MicrobPathog. 2019Mar;128:41-46.  Pubmed

2018

  1. Howlader DR, Koley H, Sinha R, Maiti S, Bhaumik U, Mukherjee P, Dutta S.Development of a novel S. Typhi and Paratyphi A outer membrane vesicles basedbivalent vaccine against enteric fever. PLoS One. 2018 Sep 14;13(9):e0203631.   Pubmed
  2. Sarkar S, Das M, Bhowmick TS, Koley H, Atterbury R, Chakrabarti AK, Sarkar BL.Isolation and Characterization of Novel Broad Host Range Bacteriophages of Vibrio cholerae O1 fromBengal. J Glob Infect Dis. 2018 Apr-Jun;10(2):84-88.   Pubmed
  3. Bhattacharya D, Ghosh D, Bhattacharya S, Sarkar S, Karmakar P, Koley H,Gachhui R. Antibacterial activity of polyphenolic fraction of Kombucha against Vibrio cholerae: targeting cell membrane. Lett ApplMicrobiol. 2018Feb;66(2):145-152  Pubmed

2017

  1. Howlader DR, Koley H, Maiti S, Bhaumik U, Mukherjee P, Dutta S. A brief review on the immunological scenario and recent developmental status of vaccines against enteric fever. Vaccine. 2017 Nov 7;35(47):6359-6366.  Pubmed
  2. Mitobe J, Sinha R, Mitra S, Nag D, Saito N, Shimuta K, Koizumi N, Koley H. An attenuated Shigella mutant lacking the RNA-binding protein Hfq provides cross protection against Shigella strains of broad serotype. PLoSNegl Trop Dis. 2017 Jul 20;11(7 )   Pubmed
  3. Sinha R, Howlader DR, Ta A, Mitra S, Das S, Koley H. Retinoic acid pre-treatment down regulates V. cholerae outer membrane vesicles induced acute inflammation and enhances mucosal immunity. Vaccine. 2017 Jun16;35(28):3534-3547.    Pubmed
  4. Ta A, Thakur BK, Dutta P, Sinha R, Koley H, Das S. Double-stranded RNA induces cathelicidin expression in the intestinal epithelial cells through phosphatidylinositol 3-kinase-protein kinase Cζ-Sp1 pathway and ameliorates shigellosis in mice. Cell Signal. 2017 Jul;35:140-153.  Pubmed
  5. Koley H, Ghosh P, Sinha R, Mitra S, Mukherjee P, Howlader DR, Chaki C, Nag D. Mice with Streptozotocin-Induced Hyperglycemia are Susceptible to Invasive Enteric Bacterial Infection. Jpn J Infect Dis. 2017 Jan 24; 70(1):111-114.   Pubmed

2016

  1. Mandal RS, Ta A, Sinha R, Theeya N, Ghosh A, Tasneem M, Bhunia A, Koley H, Das S. Ribavirin suppresses bacterial virulence by targeting LysR-type transcriptional regulators. Sci Rep. 2016 Dec 19;6:39454.  Pubmed
  2. Roy S, Patra T, Golder T, Chatterjee S, Koley H, Nandy RK. Characterization of the gluconate utilization system of Vibrio cholerae with special reference to virulence modulation. Pathog Dis. 2016 Nov;74(8).  Pubmed
  3. Ghosh A, Koley H, Pal A. The Role of Vibrio choleraecholera Haemagglutinin Protease (HAP) in Extra-Intestinal Infection. J ClinDiagn Res. 2016 Sep;10(9)  Pubmed
  4. Chourashi R, Mondal M, Sinha R, Debnath A, Das S, Koley H, Chatterjee NS. Role of a sensor histidine kinase ChiS of Vibrio cholerae in pathogenesis. Int J MedMicrobiol. 2016 Dec;306(8):657-665. Pubmed
  5. Bhattacharya D, Bhattacharya S, Patra MM, Chakravorty S, Sarkar S, ChakrabortyW, Koley H, Gachhui R. Antibacterial Activity of Polyphenolic Fraction of Kombucha Against Enteric Bacterial Pathogens. CurrMicrobiol. 2016  Pubmed
  6. Howlader DR, Sinha R, Nag D, Majumder N, Mukherjee P, Bhaumik U, MaitiS,Withey JH, Koley H. Zebrafish as a novel model for non-typhoidal Salmonella pathogenesis, transmission and vaccine efficacy. Vaccine. 2016 Sep30;34(42):5099-5106. Pubmed
  7. Sarkar P, Acharyya S, Banerjee A, Patra A, Thankamani K, Koley H, Bag PK. Intracellular, biofilm-inhibitory and membrane-damaging activities of nimbolide isolated from Azadirachta indica A. Juss (Meliaceae) against meticillin-resistant Staphylococcus aureus. J Med Microbiol. 2016 Oct;65(10):1205-1214. Pubmed
  8. Koley H, Ghosh P, Sinha R, Mitra S, Mukherjee P, Howlader DR, Chaki C, Nag D. Mice with Streptozotocin-Induced Hyperglycemia are Susceptible to Invasive Enteric Bacterial Infection. Jpn J Infect Dis. 2017 Jan 24;70(1):111-114. Pubmed

2015

  1. Nag D, Sinha R, Mitra S, Barman S, Takeda Y, Shinoda S, Chakrabarti MK, Koley H. 2015. Heat killed multi-serotype Shigellaimmunogens induced humoral immunity and protection against heterologous challenge in rabbit model. Immunobiology.220:1275-83. Pubmed
  2. Jaiswal A, Sarkar S, Das P, Nandy S, Koley H, Sarkar B. 2015. Trends in the genomic epidemiology of Vibrio cholerae O1 isolated worldwide since 1961. Int J Antimicrob Agents 46:460-4. Pubmed
  3. Withey JH, Nag D, Plecha SC, Sinha R, Koley H. 2015. Conjugated linoleic acid reduces cholera toxin production in vitro and in vivo by inhibiting Vibrio choleraeToxT activity. Antimicrob Agents Chemother. 59:7471-6. Pubmed
  4. Sinha R, Koley H, Nag D, Mitra S, Mukhopadhyay AK, Chattopadhyay B. 2015 Pentavalent outer membrane vesicles of Vibrio cholerae induce adaptive immune response and protective efficacy in both adult and passive suckling mice models. Microbes Infect. Mar;17(3):215-27. Pubmed
  5. Bhattacharya D, Dey S, Kadam S, Kalal S, Jali S, Koley H, Sinha R, Nag D, Kholkute SD, Roy S. 2015 Isolation of NDM-1-producing multidrug-resistant Pseudomonas putida from a paediatric case of acute gastroenteritis, India. New Microbes New Infect. Feb 28;5:5-9. Pubmed
  6. Rajpara N, Kutar BM, Sinha R, Nag D, Koley H, Ramamurthy T, Bhardwaj AK. 2015 Role of integrons, plasmids and SXT elements in multidrug resistance of Vibrio cholerae and Providenciavermicola obtained from a clinical isolate of diarrhea. Front Microbiol. Feb 17;6:57. Pubmed

2014

  1. Mondal M, D Nag, H Koley, DR Saha, Chatterjee NS. 2014. The Vibrio choleraeExtracellular Chitinase ChiA2 Is Important for Survival and Pathogenesis in the Host Intestine. PLoS One. 9:e103119. Pubmed
  2. Kanungo S, B Sen, T Ramamurthy, D Sur, B Manna, GP Pazhani, G Chowdhury, P Jhunjhunwala, RK Nandy, HKoley, MK Bhattacharya, S Gupta, G Goel, B Dey, M T, GB Nair, A Ghosh, D Mahalanabis.2014.Safety and immunogenicity of a live oral recombinant cholera vaccine VA1.4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India. PLoS One. 9:e99381). Pubmed
  3. Barman S, H Koley, D Nag, S Shinoda, GB Nair, Y Takeda. 2014. Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice. MicrobiolImmunol. 58:463-6. Pubmed
  4. Koley H, N Ray, G Chowdhury, S Barman, S Mitra, T Ramamurthy, AK Mukhopadhyay, BL Sarkar, R Katyal, P Das, S Panda, S Ghosh.2014. Outbreak of cholera caused by Vibrio cholerae O1 El Tor variant strain in Bihar, India. Jpn J Infect Dis.67:221-6. Pubmed
  5. Jaiswal A, H. Koley, S Mitra, DR Saha, B Sarkar. 2014.Comparative analysis of different oral approaches to treat Vibrio cholerae infection in adult mice. Int J Med Microbiol. 304:422-30. Pubmed
  6. Ghosh P, A Naha, S Basak, S Ghosh, T Ramamurthy, H. Koley, RK Nandy, S Shinoda, H Watanabe, AK Mukhopadhyay. 2014. Haitian variant tcpA in Vibrio cholerae O1 El Tor strains in Kolkata, India. J ClinMicrobiol.52:1020-1. Pubmed

2013

  1. Mitra S, MK Chakrabarti, H. Koley 2013 Multi-serotype outer membrane vesicles of Shigellae confer passive protection to the neonatal mice against shigellosis. Vaccine. 31: 3163-3173 Pubmed
  2. Sheikh IA, H. Koley, MK Chakrabarti, KM Hoque. 2013 The Epac1 signaling pathway regulates Cl- secretion via modulation of apical KCNN4c channels in diarrhea. J Biol Chem. 288: 20404-20415. Pubmed
  3. Das P, AK Singh, S Mukherjee, K Rajendran, DR Saha, H. Koley, S Basu. 2013 Composition of Escherichia coli population in the neonatal gut: phylogroups and virulence determinants. J Med Microbiol. 62: 1680-1687. Pubmed
  4. Mukherjee S, H. Koley, S Barman, S Mitra, S Datta, S Ghosh, D Paul, P Dhar. 2013 Oxalis corniculata (Oxalidaceae) leaf extract exerts in vitro antimicrobial and in vivo anticolonizing activities against Shigella dysenteriae 1 (NT4907) and Shigella flexneri 2a (2457T) in induced diarrhea in suckling mice. J Med Food. 16: 801-809 Pubmed
  5. Barman S, H. Koley, T Ramamurthy, MK Chakrabarti, S Shinoda, GB Nair, Y Takeda. 2013 Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model. Microbiol Immunol. 57: 762-771. Pubmed
  6. Rajpara N, K Vinothkumar, P Mohanty, AK Singh, R Singh, R Sinha, D Nag, H. Koley, A Kushwaha Bhardwaj. 2013 Synergistic Effect of Various Virulence Factors Leading to High Toxicity of Environmental V. cholerae Non-O1/ Non-O139 Isolates Lacking ctx Gene : Comparative Study with Clinical Strains. PLoS One. 8: e76200. Pubmed
  7. DR Saha, S Guin, R Krishnan, D Nag, H. Koley, S Shinoda, T Ramamurthy. 2013 Inflammatory diarrhea due to enteroaggregative Escherichia coli: evidence from clinical and mice model studies. Gut Pathog. 5: 36. Pubmed
  8. Jaiswal A, H. Koley, A Ghosh, A Palit, B Sarkar 2013 Efficacy of cocktail phage therapy in treating Vibrio cholerae infection in rabbit model. Microbes Infect. 15: 152-156. Pubmed

2012

  1. Mitra S, DR Saha, A Pal, Niyogi SK, U Mitra, H. Koley. 2012 Hemagglutinating activity is directly correlated with colonization ability of shigellae in suckling mouse model. Can J Microbiol. 58: 1159-1166. Pubmed
  2. Mitra S, S Barman, D Nag, R Sinha, DR Saha, H. Koley. 2012 Outer membrane vesicles of Shigella boydii type 4 induce passive immunity in neonatal mice. FEMS Immunol Med Microbiol. 66: 240-250. Pubmed
  3. China R, S Mukherjee, S Sen, S Bose, S Datta, H. Koley, S Ghosh, P Dhar. 2012 Antimicrobial activity of Sesbania grandiflora flower polyphenol extracts on some pathogenic bacteria and growth stimulatory effect on the probiotic organism Lactobacillus acidophilus. Microbiol Res. 167: 500-506. Pubmed
  4. Patra T, H. Koley, T Ramamurthy, AC Ghose, RK Nandy. 2012 The Entner-Doudoroff pathway is obligatory for gluconate utilization and contributes to the pathogenicity of Vibrio cholerae. J Bacteriol. 194: 3377-3385. Pubmed
  5. Dey T K , S. Ghosh , M. Ghosh, H. Koley, P. Dhar 2012
    Comparative study of gastrointestinal absorption of EPA DHA rich fish oil from nano and conventional emulsion formulation in rats. Food Research International , 49: 72-79

2011

  1. Barman S, DR Saha, T Ramamurthy, H. Koley. 2011 Development of a new guinea-pig model of shigellosis. FEMS Immunol Med Microbiol. 62: 304-314. Pubmed
  2. Barman S, R Kumar, G Chowdhury, DR Saha, T Wajima, T Hamabata, R Tamamurthy, GB Nair, Y Takeda, H. Koley. 2011 A live noninvasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model. Microbiol Immunol. 55, 683-693. Pubmed
  3. Mukherjee, Chaki S. Barman S., S Das., H. Koley and Dastidar Ghosh, 2011 Effective elimination of drug resistance genes in pathogenic Pseudomonas aeruginosa by antipsycholic agent thioridazine . Current Research in Bacteriology
  4. Ghosh S, Chakraborty K, Nagaraja T, Basak S, Koley H , Dutta S, Mitra U, Das S. 2011. An adhesion protein of Salmonella enterica serovar Typhi is required for pathogenesis and potential target for vaccine development. Proc Natl Acad Sci USA 108: 3348-3353. Pubmed
  5. Panda S, Pati KK, Bhattacharya MK, Koley H, Pahari S, Nair GB. 2011 Rapid situation response assessment of diarrhea outbreak in a coastal district following tropical cyclone AILA in India. Indian J Med Res. 133: 395-400. Pubmed

2010

  1. Roy, N., S Barman, A Ghosh, A Pal, K Chakraborty, SS Das, DR Saha, S Yamasaki, H. Koley. 2010. Immunogenicity and protective efficacy of Vibrio cholerae outer membrane vesicles in rabbit model. FEMS Immunol Med Microbiol. 60: 18-27. Pubmed
  2. Barman, S., S Chatterjee, G Chowdhury, T Ramamurthy, SK Niyogi, R Kumar, H. Koley 2010. Plasmid-mediated streptomycin and sulfamethoxazole resistance in Shigella flexneri 3a. Int J Antimicrob Agents. 36: 348-351. Pubmed
  3. Ghosh-Banerjee, J., M Senoh, T Takahashi, T Hamabata, S Barman, H. Koley, Mukhopadhyay AK, Ramamurthy T, Chatterjee S, Asakura M, Yamasaki S, Nair GB,Takeda Y. 2010 . Cholera toxin production by the El Tor variant of Vibrio cholerae O1compared to prototype El Tor and classical biotypes. J Clin Microbiol.48: 4283-6. Pubmed
  4. Syngkon A, S Elluri, H. Koley, P K Rompikuntal, DR Saha, MK Chakrabarti, RK Bhadra , SN Wai, A Pal. 2010 Studies on a novel serine protease of a ?hapA?prtV Vibrio cholerae O1 strain and its role in hemorrhagic response in the rabbit ileal loop model. PLoS One. 5(9). e13122. Pubmed

2009

  1. Shammas, M. A., Shmookler Reis RJ, H. Koley, Batchu RB, Li C, Munshi NC. 2009. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 113: 2290-7. Pubmed
  2. Bhowmick, T.S., H. Koley, M. Das, D. R. Saha, B. L. Sarkar. 2009. Pathogenic potential of vibriophages against an experimental infection with Vibrio cholerae O1 in the RITARD model. Int J Antimicrob Agents. 33: 569-573. Pubmed
  3. Koley, H., S. Barman, N. Roy, D. R. Saha, R. Kumar. 2009. The efficacy and immunogenicity of a live transconjugant hybrid strain of Shigella dysenteriae type 1 in two animal models. World J. Microbiol Biotechnol. 25: 679-686. Pubmed

2008

  1. Chakraborty, K., Ghosh S, H. Koley, Mukhopadhyay AK, Ramamurthy T, Saha DR, Mukhopadhyay D, Roychowdhury S, Hamabata T, Takeda Y, Das S. 2008. Bacterial exotoxins downregulate cathelicidin (hCAP-18/LL-37) and human beta-defensin 1 (HBD-1) expression in the intestinal epithelial cells. Cell Microbiol. ;10: 2520-37. Pubmed
  2. Banerjee, S., Chattopadhyay R, Ghosh A, H. Koley, Panda K, Roy S, Chattopadhyay D, Chatterjee IB. 2008 .Cellular and molecular mechanisms of cigarette smoke-induced lung damage and prevention by vitamin C. J Inflamm 11; 5: 21. Pubmed
  3. Shammas, M. A., H. Koley, R. C. Bertheau, P. Neri, M. Fulciniti, P. Tassone, S. Blotta, A. Protopopov, C. Mitsiades, R. B. Batchu, K. C. Anderson, A. Chin, S. Gryaznov, N. C. Munshi. 2008. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 22:1410-8. Pubmed
  4. Koley, H., Soumik Barman, N. Roy, D. R. Saha, R. Kumar. 2008. The efficacy and immunogenicity of a live transconjugant hybrid strain of Shigella dysenteriae type 1 in two animal models. World J. Microbiol Biotechnol. 25: 679-686.
  5. Bhowmick, R., A. Ghosal, B. Das, H. Koley, D. R. Saha, S. Ganguly, R. K. Nandy, R. K. Bhadra, N. S. Chatterjee. 2008 Intestinal adherence of Vibrio cholerae involves a coordinated interaction between colonization factor GbpA and mucin. Infect Immun. 76: 4968-77. Pubmed

2006

  1. Shammas, M. A., P. Neri, H. Koley, R. B. Batchu, R. C. Bertheau, V. Munshi, R. Prabhala, M. Fulciniti, Y. T. Tai, S. P. Treon, R. K. Goyal, K. C. Anderson, N. C. Munshi. 2006. Specific killing of multiple myeloma cells by (-) epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 108: 2804-10. Pubmed
  2. Ghosh, A., D. R. Saha, K. M. Hoque, M. Asakuna, S. Yamasaki, H. Koley, S. S. Das, M. K. Chakrabarti, A. Pal. 2006. Enterotoxigenicity of mature 45-kilodalton and processed 35-kilodalton forms of hemagglutinin protease purified from a cholera toxin gene-negative Vibrio cholerae non-O1, non-O139 strain. Infect Immun. 74: 2937-46. Pubmed

2005

  1. Shammas, M. A., H. Koley, R. B. Batchu, R. C. Bertheau, A. Protopopov, N. C. Munshi, R. K. Goyal. 2005. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol. Cancer. 15: 4-24. Pubmed

2004

  1. Koley, H., M. A. Shammas, D. G. Beer, C. Li, R. K. Goyal, N. C. Munshi. 2004. Growth arrest, apoptosis and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 126: 1337-46. Pubmed
  2. Shammas, M. A., Reis R. J. Shmookler, C. Li, H. Koley, L. H. Hurley, K. C. Anderson, N. C. Munshi. 2004 Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 10: 770-6. Pubmed

2003

  1. Shammas, M. A., Reis R. J. Shmookler, M. Akiyama, H. Koley, D. Chauhan, T. Hideshima, R. K. Goyal, L. H. Hurley, K. C. Anderson, N. C. Munshi. 2003. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2: 825-33. Pubmed

2002

  1. Shammas, M. A., H. Koley, R. K. Goyal and C. Nikhil. Munshi. 2002. Telomerase Inhibition and apoptotic cell growth arrest following telomestain treatment of multiple myeloma. Blood: 100, 11 810-15.

1999

  1. Thungapatra, M., C. Sharma, N. Gupta, R. K. Ghosh, A. Mukherjee, H. Koley, G. B. Nair and A. Ghosh. 1999. Construction of a recombinant live oral vaccine from a non-toxigenic strain in of V.cholerae O1 serotype Inaba biotype El Tor and assessment of its reactogenicity and immunogenicity in the rabbit model. Immunology Letter. 68: 219 -227. Pubmed
  2. Koley, H., Rupak Mitra, Arnab Basu, Asish K. Mukhopadhyay, P. K. Saha, B. S. Ramakrisha, Selvi Krishnan, Yoshifumi Takeda and G. Balakrish Nair. 1999. Response of Wild-type Mutants of Vibrio cholerae 01 possessing different combinations of Virulence zenes in the Ligated Rabbit Ileal Loop and in Ussing chambers: Evidence for the presence of additional secretogen. J. Med. Microbiol. 48: 51-57. Pubmed

1997

  1. Bhattacharya, S. K., M. K. Bhattacharya, D. Dutta, S. Dutta, M. Deb, A. Deb, A. G. Goswami, K .P. Das, H. Koley, G. B. Nair and A. Bagati. 1997 Double-blind, randomized clinical trial for safety and efficacy of Norfloxacin for shigellosis in children. Acta Paediatrica. 86: 319-320. Pubmed
  2. Saha, D. R., H. Koley, A. N. Ghosh and G. B. Nair. 1997. Sequential changes in gut mucosa of rabbits infected with Vibrio cholerae 0139 Bengal: an Ultrastructureal Study. J. Diarrhoeal. Dis. Res. 15: 59-64. Pubmed

1996

  1. Saha, P., H. Koley and G. B. Nair. 1996 Purification and Characterization of an extra cellular secretogenic non-membrane damaging cytotoxin produce by clinical strain of V.cholerae Non-01. Infection Immunity. 64: 3101-3108. Pubmed
  2. Saha, P., H. Koley, A. Mukherjee, S. K. Bhattacharya, G. B. Nair, B. S. Ramakrishna, S. Krishnan, Y. Takeda, 1996. Nontoxigenic Vibrio cholerae 01 Serotype Inaba Biotype EIT or Associated with a Cluster of Cased of Cholera in Southern India. Journal of Clinical Microbiology. 34: 1114-1117. Pubmed
  3. Sarkar, B. L., A. K. Chakrabarty, H. Koley, M. K. Chakrabarty and S. P. Dey. 1996. Biological activity and interaction of Vibrio cholerae bacteriopheges in rabbit ileal loop. Indian Journal of Medical Research. 104: 139-141. Pubmed
  4. Ghosh, A. R., M. Paul, H. Koley, S. K. Bhattacharya and G. B. Nair. 1996. Emergence of Shigella species in India. Lab. Medica. International. 5: 18-24.
  5. Ghosh, A. R., H. Koley, D. De, M. Paul, G. B. Nair and D. Sen. 1996. ETEC associated diarrhea among infants aged less than six months in Calcutta, India. European Journal of Epidemiology. 12: 81-84. Pubmed

1995

  1. Koley, H., A. N. Ghosh, M. Paul, A. R. Ghosh, P. K. Ganguly and G. B. Nair. 1995. Colonization ability and intestinal pathology of rabbits orally fed with Vibrio cholerae 0139 Bengal. Ind. J. Med. Res. 101: 57-60. Pubmed

1994

  1. Bhattacharya, M. K., S. K. Bhattacharya, M. Paul, D. Dutta, P. Dutta, H. Koley, D. De, A. R. Ghosh, P. Das and G. B. Nair. 1994. Shigellosis in Calcutta during 1990-1992. Antibiotic susceptibility pattern and clinical feature. J. Diarrhoeal Dis. Res. 12: 121-124. Pubmed
  2. Ghosh, A. R., H. Koley, D. De, S. Garg, M. K. Bhattacharya, S. K. Bhattacharya, G. B. Nair, T. Shimada, T. Takeda and Y. Takeda. 1994. Incidence and toxigenicity of Vibrio cholerae in a freshwater lake during the epidemic of cholera caused by serogroup O139 Bengal in Calcutta, India. FEMS Microbiol. Ecol. 14: 285-292.

© 2016   NICED,  All rights reserved.   |   Designed by :   Braindrops